Rahul Chaudhary, Facp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3964359/publications.pdf

Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 2017, 9, 76. | 1.5 | 200 |
| 2 | Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Journal of the Academy of Nutrition and Dietetics, 2020, 120, 565-586. | 0.8 | 106 |
| 3 | Role of gut microbiota in cardiovascular diseases. World Journal of Cardiology, 2020, 12, 110-122. | 1.5 | 96 |
| 4 | Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. Journal of Thrombosis and Thrombolysis, 2017, 43, 437-445. | 2.1 | 63 |
| 5 | Direct oral anticoagulants: a review on the current role and scope of reversal agents. Journal of Thrombosis and Thrombolysis, 2020, 49, 271-286. | 2.1 | 52 |
| 6 | Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 388-402. | 2.4 | 51 |
| 7 | Surgical Sepsis and Organ Crosstalk: The Role of the Kidney. Journal of Surgical Research, 2011, 167, 306-315. | 1.6 | 49 |
| 8 | Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 1890-1900. | 2.8 | 45 |
| 9 | Therapeutic Hypothermia and StentÂThrombosis. JACC: Cardiovascular Interventions, 2016, 9, 1801-1811. | 2.9 | 34 |
| 10 | Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. Thrombosis and Haemostasis, 2020, 120, 1594-1596. | 3.4 | 33 |
| 11 | Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. Thrombosis Research, 2021, 207, 150-157. | 1.7 | 24 |
| 12 | On-X Valve. Cardiology in Review, 2017, 25, 77-83. | 1.4 | 22 |
| 13 | Bilirubin in coronary artery disease: Cytotoxic or protective?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 469. | 1.1 | 22 |
| 14 | Ivabradine. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 335-343. | 2.0 | 20 |
| 15 | Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2016, 118, 1941-1947. | 1.6 | 17 |
| 16 | Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. EClinicalMedicine, 2020, 29-30, 100647. | 7.1 | 17 |
| 17 | Role of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: a Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials Journal of Atrial Fibrillation, 2019, 12, 2154. | 0.5 | 17 |
| 18 | Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 113, 40-45. | 2.2 | 16 |

RAHUL CHAUDHARY, FACP

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665. | 1.8 | 15 |
| 20 | "Blueprinting―thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. Journal of Thrombosis and Thrombolysis, 2019, 47, 192-199. | 2.1 | 14 |
| 21 | Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 373-381. | 2.1 | 14 |
| 22 | Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 454-465. | 2.1 | 14 |
| 23 | Thrombinâ€Induced Plateletâ€Fibrin Clot Strength Identified by Thrombelastography. Journal of Interventional Cardiology, 2016, 29, 168-178. | 1.2 | 13 |
| 24 | Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono―and dualâ€antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 23-35. | 3.8 | 13 |
| 25 | Effect of serum zinc and copper levels on insulin secretion, insulin resistance and pancreatic β cell dysfunction in US adults: Findings from the National Health and Nutrition Examination Survey (NHANES) 2011–2012. Diabetes Research and Clinical Practice, 2021, 172, 108627. | 2.8 | 13 |
| 26 | Bedside thromboelastography to rapidly assessÂthe pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. Journal of Thrombosis and Thrombolysis, 2021, 51, 902-904. | 2.1 | 13 |
| 27 | Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. Current Medical Research and Opinion, 2017, 33, 1979-1984. | 1.9 | 11 |
| 28 | Thirty-day readmissions after cardiac implantable electronic devices in the United States: Insights from the Nationwide Readmissions Database. Heart Rhythm, 2018, 15, 708-715. | 0.7 | 11 |
| 29 | First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition. Circulation, 2020, 142, 1305-1307. | 1.6 | 11 |
| 30 | Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19–Positive Compared With COVID-19–Negative Patients. Mayo Clinic Proceedings, 2021, 96, 1718-1726. | 3.0 | 11 |
| 31 | Cryoballoon versus Radiofrequency Ablation for Atrial Fibrillation: A Meta-analysis of 16 Clinical Trials. Journal of Atrial Fibrillation, 2016, 9, 1429. | 0.5 | 11 |
| 32 | Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. Journal of Diabetes and Its Complications, 2016, 30, 1365-1370. | 2.3 | 10 |
| 33 | Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 263-270. | 1.3 | 10 |
| 34 | His Bundle Pacing. Cardiology in Review, 2018, 26, 201-206. | 1.4 | 10 |
| 35 | Predictors of 30-day readmissions after catheter ablation for atrial fibrillation in the USA. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 243-250. | 1.3 | 10 |
| 36 | Vorapaxar in the treatment of cardiovascular diseases. Future Cardiology, 2020, 16, 373-384. | 1.2 | 10 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study. Journal of Thrombosis and Thrombolysis, 2020, 50, 484-498. | 2.1 | 10 |
| 38 | Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 673-678. | 1.6 | 9 |
| 39 | Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 495-501. | 2.4 | 9 |
| 40 | Central aortic pulse pressure, thrombogenicity and cardiovascular risk. Journal of Thrombosis and Thrombolysis, 2017, 44, 223-233. | 2.1 | 8 |
| 41 | Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs, 2020, 29, 33-47. | 4.1 | 8 |
| 42 | Safety And Efficacy Of Uninterrupted Periprocedural Apixaban In Patients Undergoing Atrial Fibrillation Catheter Ablation: A Metaanalysis Of 1,057 Patients. Journal of Atrial Fibrillation, 2016, 8, 1368. | 0.5 | 8 |
| 43 | Carotid access for transcatheter aortic valve replacement: A metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 723-733. | 1.7 | 7 |
| 44 | DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Metaâ€Analysis. Journal of the American Geriatrics Society, 2020, 68, 2021-2026. | 2.6 | 7 |
| 45 | Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients. International Journal of Cardiology, 2016, 203, 906-908. | 1.7 | 6 |
| 46 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opinion on Pharmacotherapy, 2017, 18, 123-131. | 1.8 | 6 |
| 47 | HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. Cardiovascular Revascularization Medicine, 2019, 20, 1001-1006. | 0.8 | 6 |
| 48 | Role of Internal Jugular Venous Ultrasound in suspected or confirmed Heart Failure: A Systematic Review. Journal of Cardiac Failure, 2022, 28, 639-649. | 1.7 | 6 |
| 49 | Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. International Journal of Cardiology, 2016, 218, 235-239. | 1.7 | 5 |
| 50 | Association of weight gain with coronary artery disease, inflammation and thrombogenicity. Journal of Thrombosis and Thrombolysis, 2016, 41, 394-403. | 2.1 | 5 |
| 51 | Right ventricular apical versus non-apical implantable cardioverter defibrillator lead: A systematic review and meta-analysis. Journal of Electrocardiology, 2017, 50, 591-597. | 0.9 | 5 |
| 52 | Venous Thromboembolism Prophylaxis: Inadequate and Overprophylaxis When Comparing Perceived Versus Calculated Risk. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 242-247. | 2.4 | 5 |
| 53 | Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. Atherosclerosis, 2018, 268, 55-62. | 0.8 | 5 |
| 54 | Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398. | 1.8 | 5 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Heart Failure Trial Update—Analysis of Recent Data. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2792-2800. | 1.3 | 5 |
| 56 | BRASH: Case Report and Review of Literature. Hearts, 2021, 2, 302-306. | 0.9 | 5 |
| 57 | Improving Outcomes in Cardiovascular Diseases. Cardiology in Review, 2021, Publish Ahead of Print, . | 1.4 | 4 |
| 58 | Deep Vein Thrombosis after COVID-19 Vaccinations. Blood, 2021, 138, 291-291. | 1.4 | 4 |
| 59 | Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Review of Cardiovascular Therapy, 2016, 14, 779-791. | 1.5 | 3 |
| 60 | Venous Thromboembolism Prophylaxis: Need for Continuous Assessment Due to Changes in Risk During the Same Hospitalization. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 170-175. | 2.4 | 2 |
| 61 | Telemetry: appropriateness of initial assignment and duration in nonintensive setting. American Journal of Managed Care, 2020, 26, 459-460. | 1.1 | 2 |
| 62 | Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease. Journal of Thrombosis and Thrombolysis, 2020, 50, 982-983. | 2.1 | 1 |
| 63 | Abstract 16676: Heightened Platelet Function: An Unrecognized Component of the Covid Hypercoagulability State. Circulation, 2020, 142, . | 1.6 | 1 |
| 64 | Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. World Journal of Cardiology, 2017, 9, 830-837. | 1.5 | 1 |
| 65 | Demystifying airline syncope. World Journal of Cardiology, 2020, 12, 107-109. | 1.5 | 1 |
| 66 | Coronary Artery Disease in Patients With Disorders of Bilirubin Excretion. American Journal of Therapeutics, 2017, 24, e653-e658. | 0.9 | 0 |
| 67 | Reply. JACC: Cardiovascular Interventions, 2017, 10, 105-106. | 2.9 | 0 |
| 68 | In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. Kardiologia Polska, 2019, 77, 817-819. | 0.6 | 0 |
| 69 | Six Sigma approach to reduce door-to-balloon time for patients with STEMI. American Journal of Managed Care, 2020, 26, e140-e141. | 1.1 | Ο |